Literature DB >> 20935114

Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis.

Camille Taillé1, Sabine Grootenboer-Mignot, Céline Boursier, Laurence Michel, Marie-Pierre Debray, Jérôme Fagart, Lorena Barrientos, Arnaud Mailleux, Natacha Cigna, Florence Tubach, Joëlle Marchal-Sommé, Paul Soler, Sylvie Chollet-Martin, Bruno Crestani.   

Abstract

RATIONALE: Injury to alveolar epithelial cells is central to the pathophysiology of idiopathic pulmonary fibrosis (IPF). An abnormal autoimmune response directed against antigens of the alveolar epithelium may contribute to the disease.
OBJECTIVES: To detect circulating autoantibodies (autoAbs) directed against epithelial structures.
METHODS: We performed immunoblot by separating human placental amnion extract or alveolar epithelial cell (A549 cell line) proteins on polyacrylamide gels, blotting on nitrocellulose membranes, and incubating with serum from patients with IPF (n = 40) or healthy subjects (n = 40). Proteomic analysis and mass spectrometry characterized the target protein. Inhibition experiments performed with the correspondent recombinant protein confirmed our results.
MEASUREMENTS AND MAIN RESULTS: We identified IgG autoAbs recognizing a 200-kD protein in the serum of patients with IPF. Proteomic analysis identified this protein as human periplakin (PPL), a component of desmosomes. Anti-PPL Abs were found by immunoblot in both serum and bronchoalveolar lavage in patients with IPF: 16/40 (40%) of them were positive versus none of the control subjects. Immunohistochemistry revealed that PPL was strongly expressed in bronchial and alveolar epithelium, but that PPL exhibited changes in intracellular localization among normal and fibrotic alveolar epithelium. In an alveolar epithelial wound repair assay, an anti-PPL IgG decreased cell migration. Recombinant PPL induced bronchoalveolar lavage T lymphocyte proliferation. Patients with IPF with anti-PPL Abs had a more severe respiratory disease, despite no difference in survival.
CONCLUSIONS: We found a new circulating autoAb directed against PPL in patients with IPF, associated with a more severe disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20935114     DOI: 10.1164/rccm.201001-0076OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  39 in total

Review 1.  Update in diffuse parenchymal lung disease 2011.

Authors:  Tracy R Luckhardt; Joachim Müller-Quernheim; Victor J Thannickal
Journal:  Am J Respir Crit Care Med       Date:  2012-07-01       Impact factor: 21.405

Review 2.  Idiopathic pulmonary fibrosis and a role for autoimmunity.

Authors:  Gerard F Hoyne; Hannah Elliott; Steven E Mutsaers; Cecilia M Prêle
Journal:  Immunol Cell Biol       Date:  2017-03-30       Impact factor: 5.126

3.  Pre-existing self-reactive IgA antibodies associated with primary graft dysfunction after lung transplantation.

Authors:  Vaidehi Kaza; Chengsong Zhu; Leying Feng; Fernando Torres; Srinivas Bollineni; Manish Mohanka; Amit Banga; John Joerns; T Mohanakumar; Lance S Terada; Quan-Zhen Li
Journal:  Transpl Immunol       Date:  2020-01-30       Impact factor: 1.708

4.  Identification of periplakin as a major regulator of lung injury and repair in mice.

Authors:  Valérie Besnard; Rania Dagher; Tania Madjer; Audrey Joannes; Madeleine Jaillet; Martin Kolb; Philippe Bonniaud; Lynne A Murray; Matthew A Sleeman; Bruno Crestani
Journal:  JCI Insight       Date:  2018-03-08

5.  Pre-transplant antibodies to Kα1 tubulin and collagen-V in lung transplantation: clinical correlations.

Authors:  Venkataswarup Tiriveedhi; Baskaran Gautam; Nayan J Sarma; Medhat Askar; Marie Budev; Aviva Aloush; Ramsey Hachem; Elbert Trulock; Bryan Myers; Alexander G Patterson; Thalachallour Mohanakumar
Journal:  J Heart Lung Transplant       Date:  2013-08       Impact factor: 10.247

6.  Membrane-anchored Serine Protease Matriptase Is a Trigger of Pulmonary Fibrogenesis.

Authors:  Olivier Bardou; Awen Menou; Charlène François; Jan Willem Duitman; Jan H von der Thüsen; Raphaël Borie; Katiuchia Uzzun Sales; Kathrin Mutze; Yves Castier; Edouard Sage; Ligong Liu; Thomas H Bugge; David P Fairlie; Mélanie Königshoff; Bruno Crestani; Keren S Borensztajn
Journal:  Am J Respir Crit Care Med       Date:  2016-04-15       Impact factor: 21.405

Review 7.  Personalized medicine: applying 'omics' to lung fibrosis.

Authors:  Jose D Herazo-Maya; Naftali Kaminski
Journal:  Biomark Med       Date:  2012-08       Impact factor: 2.851

8.  Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients.

Authors:  Jianmin Xue; Daniel J Kass; Jessica Bon; Louis Vuga; Jiangning Tan; Eva Csizmadia; Leo Otterbein; Makoto Soejima; Marc C Levesque; Kevin F Gibson; Naftali Kaminski; Joseph M Pilewski; Michael Donahoe; Frank C Sciurba; Steven R Duncan
Journal:  J Immunol       Date:  2013-07-19       Impact factor: 5.422

9.  BPIFB1 is a lung-specific autoantigen associated with interstitial lung disease.

Authors:  Anthony K Shum; Mohammad Alimohammadi; Catherine L Tan; Mickie H Cheng; Todd C Metzger; Christopher S Law; Wint Lwin; Jaakko Perheentupa; Helene Bour-Jordan; Jean Claude Carel; Eystein S Husebye; Filippo De Luca; Christer Janson; Ravishankar Sargur; Noémie Dubois; Merja Kajosaari; Paul J Wolters; Harold A Chapman; Olle Kämpe; Mark S Anderson
Journal:  Sci Transl Med       Date:  2013-10-09       Impact factor: 17.956

10.  Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis.

Authors:  Daryle J DePianto; Sanjay Chandriani; Alexander R Abbas; Guiquan Jia; Elsa N N'Diaye; Patrick Caplazi; Steven E Kauder; Sabyasachi Biswas; Satyajit K Karnik; Connie Ha; Zora Modrusan; Michael A Matthay; Jasleen Kukreja; Harold R Collard; Jackson G Egen; Paul J Wolters; Joseph R Arron
Journal:  Thorax       Date:  2014-09-12       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.